Biotechnology News and Research

RSS

Cardiome Pharma's board authorizes buyback of shares

Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) ("Cardiome" or the "Company") announced today that its Board of Directors has authorized management to proceed with a tender offer to purchase for cancellation up to 6,470,588 of its common shares for an aggregate purchase price of up to US$27.5 million.

26 Aug 2009

SIRO Clinpharm and CambReg Regulatory Services announces their alliance

SIRO Clinpharm, a leading Indian MNC CRO, and CambReg Regulatory Services, a UK-based pan-European regulatory services provider, announced today the formation of an exclusive strategic alliance to help companies register their products in the European market.

26 Aug 2009

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

26 Aug 2009

PD2i algorithm published in Therapeutics and Clinical Risk Management can predict risk of sudden cardiac death

David H. Fater, CEO of Vicor Technologies, Inc., today announced that original research conducted using its PD2i algorithm to prospectively predict risk of sudden cardiac death was published in Therapeutics and Clinical Risk Management.

26 Aug 2009

FDA to review Acorda Therapeutics’ NDA for Fampridine-SR

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has confirmed that its Peripheral and Central Nervous System Drugs Advisory Committee will review the Company’s New Drug Application (NDA) for Fampridine-SR on October 14, 2009.

26 Aug 2009

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.

26 Aug 2009

Interactive Intelligence's CIC communications software suite deployed at WRB Communications

WRB Communications, a medical information call center services company, has deployed the Interactive Intelligence (Nasdaq: ININ) all-in-one IP communications software suite, Customer Interaction Center® (CIC).

26 Aug 2009

Gates Foundation awards $4.8M grant for improving sanitation systems in developing world

The Bill & Melinda Gates Foundation recently awarded a $4.8 million grant to the London School of Hygiene and Tropical Medicine to study and improve sanitation systems in the developing world, the Seattle Times' blog, "The Business of Giving" reports.

26 Aug 2009

Biotime completes the process of issuing common shares and warrants under its revolving line of credit agreement

BioTime, Inc. (OTCBB: BTIM) announced today that it has completed an Exchange Offer to the holders of notes issued under its revolving line of credit agreement. BioTime issued 1,989,515 common shares and warrants to purchase 100,482 common shares in exchange for notes in the aggregate principal amount of $3,349,259.

25 Aug 2009

Genome BC's research projects to determine efficient methods of liberating fermentable sugars from dead pine

In order to reduce the Province's greenhouse gas emissions, the BC Bioenergy Strategy is calling for greatly increased production of renewable biofuels such as ethanol, from biomass grown in BC. Two new research projects, largely funded by Genome BC, will help to answer these questions and unlock the valuable green energy found within BC's forests.

25 Aug 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

CenterWatch senior edtior to deliver keynote address at KIKA’s U.S. User Group Meeting

KIKA Clinical Solutions announced that Sara Gambrill, Senior Editor of CenterWatch, will be a keynote speaker at KIKA’s U.S. User Group Meeting. KIKA is the leading provider of advanced EDC solutions for clinical trials, and creators of the Veracity Web-based platform for Clinical Asset Management. The User Group Meeting will take place October 21 and 22 in Boston.

25 Aug 2009

Illumina's new stock repurchase program effective in returning value to shareholders

Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the Company to repurchase in the aggregate up to $75 million of its outstanding common stock.

From Illumina, Inc. 25 Aug 2009

Bavarian Nordic begins negotiations with U.S. to secure a contract to develop a freeze-dried version of smallpox vaccine

Bavarian Nordic A/S (OMX: BAVA) announced today that the US authorities have initiated negotiations for a new contract to develop a freeze-dried version of the IMVAMUNE(R) smallpox vaccine.

25 Aug 2009

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics, Inc. today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company’s proprietary ADC technology.

25 Aug 2009

Malaysian biotechnology industry expected to grow by revenue at an average rate of 15 percent per year

Malaysia's plans for its biotechnology sector remain ambitious even with the recent global meltdown. By 2020 the government envisages this sector will employ up to 160,000 people and will contribute to 5% of Malaysia's GDP.

25 Aug 2009

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Cobroxin, an over-the-counter (OTC) treatment for stage 2 (moderate to severe) chronic pain.

25 Aug 2009

Research to be conducted on bacterial microbes in space to discover new medicines

Along with supply and equipment cargo bound for the International Space Station, Space Shuttle Discovery STS-128 will carry an additional scientific payload being conducted by Austin-based Astrogenetix, the first commercial space company to use microgravity to discover the foundation of new medicines.

25 Aug 2009

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Diagnostic HYBRIDS announces the FDA clearance, for marketing under the 510(k) pre-notification process, of the Thyretain TSI Reporter BioAssay. Thyretain is an in vitro diagnostic use test that specifically detects auto-antibodies called thyroid stimulating immunoglobulins (TSI) in patient serum.

25 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

Biotechnology News and Research

Cardiome Pharma's board authorizes buyback of shares

SIRO Clinpharm and CambReg Regulatory Services announces their alliance

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

PD2i algorithm published in Therapeutics and Clinical Risk Management can predict risk of sudden cardiac death

FDA to review Acorda Therapeutics’ NDA for Fampridine-SR

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Interactive Intelligence's CIC communications software suite deployed at WRB Communications

Gates Foundation awards $4.8M grant for improving sanitation systems in developing world

Biotime completes the process of issuing common shares and warrants under its revolving line of credit agreement

Genome BC's research projects to determine efficient methods of liberating fermentable sugars from dead pine

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CenterWatch senior edtior to deliver keynote address at KIKA’s U.S. User Group Meeting

Illumina's new stock repurchase program effective in returning value to shareholders

Bavarian Nordic begins negotiations with U.S. to secure a contract to develop a freeze-dried version of smallpox vaccine

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Malaysian biotechnology industry expected to grow by revenue at an average rate of 15 percent per year

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Research to be conducted on bacterial microbes in space to discover new medicines

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Biotechnology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News